A 72-year-old man is brought to the emergency department by his family due to a rapidly ex… — USMLE Step 3

A $72$ -year-old man is brought to the emergency department by his family due to a rapidly expanding, painful swelling in his right thigh over the past $24$ hours. He denies any significant trauma, reporting only a minor bump against a doorway. His medical history is significant for rheumatoid arthritis and hypertension. Current medications include methotrexate, amlodipine, and occasionally ibuprofen.

Vital signs show a temperature of $37.1^\circ C$ ( $98.8^\circ F$ ), heart rate of $118$ /min, blood pressure of $98/62$ mmHg, and respiratory rate of $20$ /min. Physical examination reveals a massive, tense, ecchymotic hematoma encompassing the right posterior thigh.

Laboratory studies are obtained:

Test	Result	Reference Range
Hemoglobin	$7.2$ g/dL	$13.5-17.5$ g/dL
Platelet count	$285,000/\mu L$	$150,000-400,000/\mu L$
Prothrombin time (PT)	$12.3$ s	$11-14$ s
Activated partial thromboplastin time (aPTT)	$94$ s	$25-40$ s
Fibrinogen	$360$ mg/dL	$150-400$ mg/dL

A mixing study is performed using a $1:1$ ratio of the patient's plasma and normal pooled plasma. The aPTT immediately corrects to $32$ s. However, after incubation at $37^\circ C$ for $2$ hours, the aPTT prolongs to $82$ s.

The patient remains tachycardic, and the hematoma appears to be enlarging. Which of the following best describes the mechanism of action of the most appropriate immediate pharmacotherapy for this patient?

Directly activates factor X on the surface of activated platelets independent of the intrinsic tenase complexAnswer
B
Administers a bispecific monoclonal antibody that bridges activated factor IX and factor X to substitute for the missing cofactor
C
Provides a concentrated source of the deficient procoagulant glycoprotein to competitively saturate circulating neutralizing antibodies
D
Replenishes non-activated vitamin K-dependent factors to rapidly restore the common coagulation pathway
E
Stimulates endothelial Weibel-Palade bodies to release stored von Willebrand factor and endogenous factor VIII

Answer

The correct answer is the pharmacotherapy that directly activates factor X on the surface of activated platelets independent of the intrinsic tenase complex.

The patient's presentation of spontaneous severe hemorrhage, isolated prolonged aPTT, and a mixing study that corrects immediately but prolongs after incubation is pathognomonic for acquired hemophilia A (factor VIII autoantibodies). The immediate priority for life-threatening bleeding in these patients is hemostatic control with a bypassing agent, such as recombinant activated factor VII (rFVIIa) or activated prothrombin complex concentrate (aPCC). Recombinant FVIIa works by directly binding to the surface of activated platelets at the site of injury and activating factor X to factor Xa, thereby completely bypassing the need for the factor VIIIa/IXa (intrinsic tenase) complex to generate a thrombin burst.

Step-by-Step Solution

Assess the patient's clinical stability and primary presentation.

The patient has a life-threatening spontaneous hemorrhage (massive thigh hematoma, severe hemoglobin drop) with hemodynamic compromise (tachycardia, hypotension).

Recognizing a hemorrhagic emergency dictates the need for immediate hemostatic control rather than long-term definitive therapy.

Interpret the initial coagulation panel.

The patient has an isolated, markedly prolonged aPTT with a normal PT and platelet count.

An isolated aPTT prolongation points to an intrinsic pathway defect (factors XII, XI, IX, or VIII) rather than a common pathway or platelet issue.

Analyze the results of the immediate and incubated mixing studies.

Immediate correction suggests a factor deficiency, but subsequent prolongation after 2-hour incubation is the pathognomonic hallmark of a time- and temperature-dependent inhibitor.

This specific pattern confirms the diagnosis of Acquired Hemophilia A (autoantibodies against factor VIII), which is highly associated with autoimmune conditions like rheumatoid arthritis.

Determine the optimal pharmacologic intervention for acute bleeding in this specific condition.

The primary treatment requires bypassing agents (such as recombinant activated factor VII or activated prothrombin complex concentrate) rather than standard factor VIII replacement.

Because the circulating autoantibodies are active and high-titer, giving standard factor VIII or stimulating its release will fail, as the new factor will simply be neutralized.

Identify the molecular mechanism of the selected bypassing agent.

Recombinant activated factor VII (rFVIIa) works by directly activating factor X on activated platelets, completely bypassing the inhibited factor VIII in the intrinsic tenase complex.

The question specifically asks for the mechanism of action of the most appropriate immediate therapy.

Key Concept

Diagnosis of Acquired Hemophilia A via incubated mixing study and acute management using bypassing agents.

Alternative Method

While recombinant activated factor VII (rFVIIa) is heavily favored in this description, activated prothrombin complex concentrate (aPCC, also known as FEIBA) is an equally valid alternative bypassing agent for acute bleeding in acquired hemophilia A. Its mechanism involves providing pre-activated factor IXa and factor Xa to bypass the inhibitor.

Estimated Time:2m 0s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Alternative Method

Topics

More questions from this topic